Experimental validation confirmed Mt2's dual regulatory function: its inhibition reduced NOS2 expression—a key mediator of vascular tone—and concurrently decreased migraine‐related inflammatory markers, including CGRP, IL‐6, and TNF‐α [7, 31, 32]. The gene discussed is IL6; the disease is migraine disorder.